RECRUITING

A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties

Conditions

Blood Cancer Lymphoma Leukemia Myeloma Blood cancer survivor Memorial Sloan Kettering Cancer Center 25-119

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Research has shown that music-based activities may help improve brain functions, such as attention, memory, and executive function. Because of this past research, the researchers are doing this study to find out whether telehealth music therapy is a practical treatment for cognitive difficulties in blood cancer survivors. The researchers will also study whether music therapy and music education help improve cognitive function and other common symptoms such as anxiety, depression, and/or tiredness.

Official Title

Pilot Trial of Telehealth Music Therapy for Cognitive Dysfunction in Hematologic Cancer Survivors (PRELUDE)

Quick Facts

Study Start:2025-06-27

Study Completion:2025-12-27

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT07052916

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* English-proficient, aged 18 or older * Diagnosis of lymphoma, leukemia, or myeloma * Stable oncologic disease or no evidence of disease as indicated in the medical chart or by the oncology team * Score of \<54 on the FACT-Cog PCI subscale * Minimum life expectancy of one year as per clinician assessment * Patient should be able to understand and complete all study assessments on their own. * Eligible patient should be able to understand informed consent and provide signed informed consent in English.	* Less than 3 months since completion of surgery, radiation, induction chemotherapy (for newly diagnosed or relapsed disease), transplantation, or immunotherapy (e.g., CAR T-Cell, bispecific antibodies) * If there is a defined treatment period, the patient must be at least 3 months from treatment completion * If the patient is on continuous therapy, patient must have completed at least 6 months of the therapy * Maintenance therapies are allowed * Received music therapy (MT) in the past year * Current music training, \>6 months of music training in the past 10 years, or plan to initiate music training during the study * No access to an internet-connected device * Active suicidal ideation, bipolar, schizophrenia, or substance abuse * BOMC score ≥10 (indicative of dementia) * Uncorrectable visual, auditory, or motor impairments * Initiation or altered dose of sedative, stimulant, or anti-cholinergic medications in the past month or plan to initiate these medications during the study, as these are known to impact cognitive function * Initiation of any other interventions for CRCD (e.g., cognitive rehabilitation) in the past month or plan to initiate these interventions during the study, as these are known to impact cognitive function

Inclusion Criteria

Exclusion Criteria

* English-proficient, aged 18 or older
* Diagnosis of lymphoma, leukemia, or myeloma
* Stable oncologic disease or no evidence of disease as indicated in the medical chart or by the oncology team
* Score of \<54 on the FACT-Cog PCI subscale
* Minimum life expectancy of one year as per clinician assessment
* Patient should be able to understand and complete all study assessments on their own.
* Eligible patient should be able to understand informed consent and provide signed informed consent in English.

* Less than 3 months since completion of surgery, radiation, induction chemotherapy (for newly diagnosed or relapsed disease), transplantation, or immunotherapy (e.g., CAR T-Cell, bispecific antibodies)
* If there is a defined treatment period, the patient must be at least 3 months from treatment completion
* If the patient is on continuous therapy, patient must have completed at least 6 months of the therapy
* Maintenance therapies are allowed
* Received music therapy (MT) in the past year
* Current music training, \>6 months of music training in the past 10 years, or plan to initiate music training during the study
* No access to an internet-connected device
* Active suicidal ideation, bipolar, schizophrenia, or substance abuse
* BOMC score ≥10 (indicative of dementia)
* Uncorrectable visual, auditory, or motor impairments
* Initiation or altered dose of sedative, stimulant, or anti-cholinergic medications in the past month or plan to initiate these medications during the study, as these are known to impact cognitive function
* Initiation of any other interventions for CRCD (e.g., cognitive rehabilitation) in the past month or plan to initiate these interventions during the study, as these are known to impact cognitive function

Contacts and Locations

Study Contact

Kevin Liou, MD

CONTACT

646-608-8563

liouk@mskcc.org

Jun Mao, MD, MSCE

CONTACT

646-608-8552

maoj@mskcc.org

Principal Investigator

Kevin Liou, MD

PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering Basking Ridge (All protocol activities)

Basking Ridge, New Jersey, 07920

United States

Memorial Sloan Kettering Monmouth (All protocol activities)

Middletown, New Jersey, 07748

United States

Memorial Sloan Kettering Bergen (All protocol activities)

Montvale, New Jersey, 07645

United States

Memorial Sloan Kettering Cancer Center Suffolk - Commack (All protocol activities)

Commack, New York, 11725

United States

Memorial Sloan Kettering Westchester (All protocol activities)

Harrison, New York, 10604

United States

Memorial Sloan Kettering Cancer Center (All protocol activities)

New York, New York, 10065

United States

Memorial Sloan Kettering Nassau (All protocol activities)

Uniondale, New York, 11553

United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

Kevin Liou, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-06-27

Study Completion Date2025-12-27

Study Record Updates

Study Start Date2025-06-27

Study Completion Date2025-12-27

Terms related to this study

Keywords Provided by Researchers

Blood cancer survivor
myeloma
Leukemia
Lymphoma
Memorial Sloan Kettering Cancer Center
25-119

Additional Relevant MeSH Terms

Blood Cancer
Lymphoma
Leukemia
Myeloma